Biogen qualifies for the Enterprising Investor but not the Defensive Investor. The Defensive Investor has concerns with the short dividend record and the high PEmg and PB ratios, while the Enterprising Investor’s only concern is the lack of dividend payments.
Category: Pharmaceuticals
Vertex Pharmaceuticals Annual Valuation – 2014 $VRTX
Vertex Pharmaceuticals does not qualify for either the Defensive Investor or the Enterprising Investor. The Defensive Investor has major concerns with the lack of earnings stability over the last ten years, the lack of dividends, the insufficient earnings growth, and the high PEmg and PB ratios.
Amgen Inc. Quarterly Valuation – June 2014 $AMGN
Amgen Inc. is suitable for Enterprising Investors but not for Defensive Investors. The Defensive Investor has concerns with the lack of a long enough dividend record and the high PB ratio.
Abbott Labs Quarterly Valuation – June 2014 $ABT
Abbott Labs is suitable for the Enterprising Investor but not the Defensive Investor, who is concerned with the low current ratio and the lack of sufficient earnings growth over the last ten years. The Enterprising Investor is only concerned with the lack of earnings growth over the last five years.
Pfizer Inc. Quarterly Valuation – June 2014 $PFE
Pfizer achieves a rare feat, which is satisfying all of the requirements of both the Defensive Investor and the Enterprising Investor. Not many companies meet this level of low-risk, and as a result, both investor types should have few concerns about the financial stability of the company.
Johnson & Johnson May 2014 Quarterly Valuation $JNJ
Johnson & Johnson qualifies for Enterprising Investors but not for Defensive Investors. The Defensive Investor is concerned with the high PEmg and PB ratios, but the company passes all of the requirements of the Enterprising Investor.
McKesson Corp (MCK) Annual Valuation – 2014
McKesson Corp is not suitable for either the Defensive Investor or the Enterprising Investor. The Defensive Investor has concerns with the low current ratio, lack of earnings stability over the last ten years, and the high PEmg and PB ratios, while the Enterprising Investor is concerned with the high level of debt relative to the current assets.
Celgene Corp (CELG) Quarterly Valuation – May 2014
Celgene Corp is suitable for the Enterprising Investor but not the Defensive Investor. The Defensive Investor is concerned with the lack of earnings stability over the last ten years, lack of dividends, and the high PEmg and PB ratios.
Regeneron Pharmaceuticals Inc. (REGN) Annual Valuation – 2014
Regeneron Pharmaceuticals is not suitable for either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company has shown insufficient earnings stability or growth over the ten year historical period, does not pay dividends, and is trading at a high PEmg ratio.